Hemab Therapeutics Initiates Phase III Trial for Sutacimig and Projects Cash Runway into 2029
Hemab Therapeutics Holdings, Inc. (COAG) has announced the initiation of a pivotal Phase III clinical trial for its candidate sutacimig, targeting approximately 75 patients. This milestone represents a significant step in the company's clinical development pipeline as it moves toward potential regulatory approval. In addition to the clinical update, management provided guidance on the company's financial position, stating that current cash reserves are expected to fund operations through 2029. This extended runway provides the company with substantial stability to advance its research and development efforts without immediate liquidity concerns.
Tickers: $COAG